Saol Therapeutics

CompanyUnited States

Saol Therapeutics develops one asset, in phase 3 (SL1002 in chronic pain related to osteoarthritis of the knee). Mostly small molecule; based in the United States.

1
Asset
Furthest stage: Phase 3; 0
Trials: 0
Signals

Pipeline

1

SL1002
Neurolytic formulation providing prolonged pain relief or spasticity reduction
Phase 3, Small molecule, chronic pain related to osteoarthritis of the knee, spasticity (Phase 2)

Full company profiles: pipeline, trials, funding and people.